This is the authors' abstract. We don't add key points for this paper.
Purpose: To validate the effectiveness of fecal DNA Syndecan-2 methylation (m SDC2 ) test in the detection of colorectal cancer in high-risk population in China. This may provide evidence-based data of diagnostic or screening for colorectal cancer in China. Methods A high-risk Chinese pilot comprising 1130 individuals aged 40-79 was registered for colorectal cancer (CRC) detection using the fecal m SDC2 test. The sensitivity and specificity to CRC, advanced adenomas (AA), and advanced colorectal neoplasia (ACN) were estimated. High-risk factors for incidence of colorectal lesions were analyzed and then were constructed a logistic regression model to better reflect the efficacy of the fecal m SDC2 test. Results According to established criteria, 1035 high-risk individuals were included for analysis. Among them, 16 CRCs (1.55%), 65 AAs (6.28%), 189 NAAs (18.26%), and 150 polyps (14.49%) were defined by colonoscopy and pathological examination. The sensitivity of m SDC2 test to CRC and AA was 87.50% and 40.00%. The specificities were 95.61% in the others group. The positive predictive value (PPV) of m SDC2 test for CRC, AA, and ACN was 16.09%, 29.89% and 45.98%, respectively. In addition, the negative predictive value (NPV) of m SDC2 test for CRC was 99.79%. The positive of m SDC2 test is a significant risk signal for the occurrence of ACN (P <0.001) after adjusting other high-risk covariates. Conclusion The results of this CRC screening showed that offering a combination of fecal m SDC2 test and colonoscopy may be an active option to early detect malignant lesions of the colorectum in Chinese high-risk population.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: